Article
作者: Su, Hang ; Xie, Huikang ; Gao, Jiani ; Wang, Fang ; Ren, Yijiu ; Wu, Chunyan ; Chen, Jianxia ; Cao, Yajuan ; Wu, Jun ; Xu, Long ; Xu, Zhu ; Lu, Huinan ; Xi, Jianzhong Jeff ; Dang, Yifang ; Gu, Jijie ; Wang, Fei ; Zhang, Hang ; Chen, Li ; Xu, Junfang ; Zheng, Mengge ; Wu, Xiangyang ; Ma, Mingtong ; Yin, Shenyi ; Liu, Haipeng ; Chen, Chang ; Fei, Yiyan ; Ge, Baoxue ; Su, Chunxia
Enhancing chemosensitivity is one of the largest unmet medical needs in cancer therapy. Cyclic GMP-AMP synthase (cGAS) connects genome instability caused by platinum-based chemotherapeutics to type I interferon (IFN) response. Here, by using a high-throughput small-molecule microarray-based screening of cGAS interacting compounds, we identify brivanib, known as a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor, as a cGAS modulator. Brivanib markedly enhances cGAS-mediated type I IFN response in tumor cells treated with platinum. Mechanistically, brivanib directly targets cGAS and enhances its DNA binding affinity. Importantly, brivanib synergizes with cisplatin in tumor control by boosting CD8+ T cell response in a tumor-intrinsic cGAS-dependent manner, which is further validated by a patient-derived tumor-like cell clusters model. Taken together, our findings identify cGAS as an unprecedented target of brivanib and provide a rationale for the combination of brivanib with platinum-based chemotherapeutics in cancer treatment.